Lisa Kopp Johnson is a Chicago seller who has worked for both sides of the ad tech fight. She sold media for Undertone and Amobee. She sold the buy side at The Trade Desk. Then she sold the grading system at Integral Ad Science. In September 2026, AdExchanger named her a Top Women in Media & Ad Tech honoree in the Team Leadership category. The listing gave her title and company and nothing more: Chief Revenue Officer, DeepIntent.

Her current job is harder than any of the earlier ones. DeepIntent is a demand-side platform that buys ads aimed at doctors and at the patients those doctors treat, using health data that the company says has been stripped of identity. In the last three years the Federal Trade Commission sued to keep it out of IQVIA's hands, a private equity firm bought a majority of it for $637 million, the White House came after drug advertising, and a string of states rewrote their health privacy rules. Kopp Johnson runs the sales team that has to keep that revenue growing anyway.

Kopp Johnson learned the trade in the Midwest, where the clients are big and conservative and expect you to show up in person. Her early sales leadership jobs were at CoolSavings, the coupon network, and at Undertone, the high-impact display shop.

At Amobee, the Singtel-owned ad platform, she led sales for the Midwest and West Coast, two regions with very different buyers. Chicago's holding company agencies and CPG brands plan in quarters. The West Coast's tech and entertainment buyers plan in sprints.

Two regions, two speeds, one quota. That is the résumé of someone who gets put in charge of other sellers.

By her own account, published later by IAS, the three words that describe her are "Warm, Strategic & Action Driven (technically 4 words!)." A seller who counts the ampersand and corrects herself is a seller who reads the contract.

On December 4, 2019, The Trade Desk named her General Manager, Midwest Business Development. It was the largest independent DSP in the market, and the Chicago role meant bringing the big regional advertisers onto it directly.

Stacy Bohrer, then The Trade Desk's regional vice president, introduced her in the announcement: "Lisa has been a major presence in the Midwest advertising industry for several years, and we are thrilled to bring her business development expertise to The Trade Desk." Bohrer added: "Her leadership experience with name-brand companies in the region will be a major boost as they look to drive more data-driven decisioning into their ad campaigns."

Kopp Johnson gave the expected answer, and it is still useful because it is the same pitch she makes now about another DSP: "More and more companies are developing integrated digital ad campaigns across channels and devices, and they understand The Trade Desk's unique ability to help them leverage data to optimize impact and value."

She also said: "The Trade Desk's vision, product leadership and executive team position the company at the forefront of this fast-growing industry."

Keep the phrase "leverage data" in mind. At The Trade Desk, the data was cookies and IDs. At DeepIntent, it is diagnoses and prescriptions.

Around late 2021, she moved to Integral Ad Science as SVP of Global Agency Development & Brand Partnerships. IAS sells verification, the brand safety and viewability scoring that holding companies have to answer to. Her job was the agency relationships.

In an IAS "Masters of Media" Q&A dated March 28, 2022, she said she had joined "about 6 months ago." She called the agency problem of the year by name: "It's becoming increasingly more challenging for marketers to have a holistic approach to their media strategies." Her examples were retail media and CTV.

She was candid about the job's other half: "What I continually try to chase is finding the right balance of being a working mother and a sales leader."

She said the best advice she had received was to "always take the high road," because "you'll never be sorry you did."

And she gave the best answer anyone in ad tech has offered to the jargon question: "The "Year of"! Year of Mobile, Year of CTV….can't stand the pressure this puts on us all."

The line has aged well. Her current employer now sells "the year of" point-of-care, EHR and agentic AI, often in the same press release.

On January 16, 2024, DeepIntent named Kopp Johnson chief revenue officer and Adam Kapel chief marketing officer. The timing tells you what she walked into.

Seventeen days earlier, on December 29, 2023, Judge Edgardo Ramos of the Southern District of New York had granted the FTC a preliminary injunction blocking IQVIA, the health data giant, from buying DeepIntent's parent, Propel Media. On the day DeepIntent announced its new CRO, the parties filed a joint motion to dismiss the FTC's administrative case because the deal was dead. The Commission dismissed it on February 2, 2024.

So the company had stopped planning to be acquired and had to start planning to grow. It needed a sales leader from outside pharma who could run a revenue team as a business rather than as a relationship.

Founder and CEO Chris Paquette said so in the release: "I am thrilled to have these two proven and experienced executives join DeepIntent. It is our mission to meaningfully improve health outcomes via advertising and technology." He credited "Lisa's ability to connect with our clients and mobilize a team to tell our story" and said the two hires "positions us well to achieve that mission and scale our business."

Kopp Johnson said: "I'm delighted to step into the role of leading the sales organization at a pivotal moment in the company's growth. I'm eager to collaborate with this incredibly talented team to drive meaningful revenue growth and cultivate lasting industry relationships."

The seat had a history. In August 2022, DeepIntent hired its first COO, Amit Chaturvedi, from WarnerMedia, and said his "primary focus will be further integrating and scaling DeepIntent's sales, campaign management, client success & business development teams." The marketing chief hired alongside her didn't last. Kapel left in 2024, and the job stayed vacant until Ian Colley, The Trade Desk's former CMO, arrived in April 2026. With Colley, DeepIntent now has two Trade Desk alumni running its revenue and marketing.

The clearest public description of DeepIntent's market position is in the government's case against its sale, not in its marketing.

The FTC's administrative complaint calls DeepIntent one of the three main healthcare DSPs, one of the top two firms in programmatic advertising to healthcare professionals, and "the only significant unintegrated healthcare DSP" left in the market. It quotes DeepIntent's own chief technology officer: "Not long ago, there was no such thing as a healthcare DSP." The share figures are redacted.

At the hearing, the FTC's expert put the combined DeepIntent and IQVIA's Lasso at 46% of the HCP programmatic market. The defendants' own expert put it at 30.6%. The court ruled that even the defense number met the 30% presumption of harm.

The money came after that. On September 9, 2025, Vitruvian Partners, the London growth investor, took a majority stake in a deal valued at $637 million. It was Vitruvian's first ad tech investment. Paquette told AdExchanger the company had "grown primarily organically for the past seven or eight years" under Propel, and that outside capital meant "we could ramp up the product, do more hiring, potentially do M&A." He also said: "This investment validates what we've been saying for awhile."

AdExchanger put headcount at about 380. DeepIntent says it serves 19 of the top 20 global life sciences companies. In October 2025, SLR Digital Finance gave it a $40 million revolving credit line running to September 2030. That was a step down from the $80 million in availability SLR had built up over three years, and SLR said the new facility was sized to current needs.

Revenue has never been published. Propel Media stopped reporting financials in 2019. In an August 2025 investor letter, Cedar Creek Partners, a fund that held Propel stock, estimated 2023 revenue at $112 million to $150 million, up nearly 25%. That is an outside shareholder's estimate, not a company figure. If it is roughly right, Vitruvian paid a growth-stage price for a business growing at a mature company's rate, and closing that gap is Kopp Johnson's job.

Kopp Johnson does not give many interviews. Most of what she says in public comes from panels and partnership releases, and DeepIntent's own blog is the main record of the panels.

At Fierce Pharma Week 2025, on a panel with media leads from Bayer, Amgen and Merck, she made the case for a vertical DSP: "Everything we do, from planning to optimization to measurement, is designed for healthcare."

On timing: "During a person's health journey, it matters when you reach them." DeepIntent's writeup ties that line to the company's daily refresh of claims data.

On regulation, she said more than most CROs would: "Five new states have recent regulatory changes or ones coming up. Change is constant." Her next line: "But because this is all we do, our entire business is built on being privacy-first."

Her prediction: "The ability to precisely reach hard-to-reach patient populations is where our industry is going." The writeup says she pointed to rare disease, which DeepIntent puts at 72% of new drug approvals.

At DeepIntent's AdLab event on live sports and CTV, published April 2026, she hosted and said streaming environments become "real strategic, measurable channels that can drive outcomes."

The 2026 releases follow one plan: move DeepIntent closer to the moment a doctor writes the prescription. On May 21, 2026, DeepIntent said it would be the first healthcare DSP to integrate OptimizeRx's authenticated EHR network, with Kopp Johnson saying: "This partnership comes as DeepIntent is building the richest marketplace of vital inventory relevant to our clients." On May 28, it announced Lane4.io, an EHR-focused SSP reaching about 158,000 doctors across six EHR systems, with targeting at the level of the individual prescriber's NPI number. Her line: "This partnership gives our clients extended reach and scale to activate true omnichannel strategies."

Translation: ads inside the software doctors use while treating patients, bought programmatically, with triggers aimed at individual prescribers. That inventory pays very well. It is also the kind regulators study closely.

Everything she sells depends on one claim, so read it carefully.

DeepIntent's homepage calls the platform "HIPAA and NAI-compliant" and advertises "250M+" patient profiles. Its audiences page FAQ says "300M+" de-identified patients, so the company's own pages give two different figures. The same FAQ says a third-party expert found the re-identification risk "below the HIPAA expert determination standard," and that patient audiences can be built from "IQVIA and/or Symphony Health data."

That gives the profile its central irony. IQVIA is the company the FTC stopped from buying DeepIntent, and it is still a data source DeepIntent sells. The FTC complaint noted that DeepIntent markets itself as "fully integrated with IQVIA" data, and argued that IQVIA could withhold that data from competitors after a merger. The merger failed. The data relationship, as DeepIntent's own pages describe it, is still there.

The wording of the claim has also changed. DeepIntent's 2020 launch release for patient targeting called the product "HIPAA-certified," citing a disclosure risk assessment by Mirador Analytics, and Paquette said the method was "mathematically guaranteeing HIPAA compliance." HHS does not certify HIPAA compliance. The current FAQ language, "below the HIPAA expert determination standard," is narrower and more defensible.

In December 2024, DeepIntent launched Data HealthChecks, labeling third-party data vendors that pass an annual review of consent practices and sensitive-data handling. DeepIntent runs that review itself. No outside auditor is named.

The rules keep tightening outside HIPAA, which is where ad tech operates. The FTC's expanded Health Breach Notification Rule took effect July 29, 2024. It treats unauthorized sharing of health app data for ad targeting as a breach, and the FTC had already used it against GoodRx and Premom. Washington's My Health My Data Act requires separate consent for consumer health data and lets individuals sue. The first such suit, against Amazon, was filed February 10, 2025, over location data the plaintiff argued could reveal clinic visits. New York's legislature passed a broad health privacy bill. Governor Kathy Hochul vetoed it on December 19, 2025, citing definitions and scope that were "broad," and a revised version returned in 2026.

Paquette's view, given to AdExchanger the week of the Vitruvian deal, is that these laws "are actually a tailwind for us." That is the pitch Kopp Johnson's team takes to pharma clients: the rules get harder, the generalist DSPs leave, and the specialist keeps the budget. It is a reasonable bet. It also depends on DeepIntent's de-identification holding up every time a new state writes a new definition of health data.

Pharma buyers want one number: did the ad produce prescriptions. Paquette told AdExchanger in 2023 that clients want attribution tied to scripts written, and that pharma and programmatic were converging: "The two worlds are colliding."

DeepIntent's main proof is its own. The DeepIntent Outcomes product page says: "During our beta testing period, a top pharmaceutical company found that Outcomes drove script lift by up to 35%." The case study behind it describes a case-control study run with an unnamed agency and its largest pharma client. It reports 10% to 15% higher prescriptions against HCP-only exposure, 25% higher new prescriptions against control for one brand, and 35% higher total prescriptions against control for another.

Those are three numbers against two different baselines, combined into one "10-35%" headline. The published case study does not give sample size, study length, how the control group was matched, or statistical significance. It came from a beta, it was measured with DeepIntent's own tool, and DeepIntent published it. A 2020 company release reported an average client script lift of 10% to 35%, the same range.

The industry-level research has the same structure. In October 2024, MAGNA and DeepIntent published "Beyond the Prescription," an online survey of about 1,166 patients and 1,001 doctors. It found that more than half of patients said an ad helped them discover a health condition. DeepIntent repeated the finding in its Vitruvian announcement. The same survey found that just 31% of patients trust pharma messaging. It was co-produced by a company that sells pharma ads.

That doesn't make the findings false. It makes them vendor research, and a buyer should treat them that way. A CRO selling outcomes is selling the vendor's own measurement until someone independent runs the test.

On the morning of September 9, 2025, DeepIntent announced its $637 million deal. That same day, the President signed a memorandum directing HHS and the FDA to go after prescription drug ads the administration called misleading.

The FDA's response was large. It sent roughly 100 cease-and-desist letters and about 40 untitled letters to drugmakers. It also put on its regulatory agenda a proposed rule to eliminate the "adequate provision" that lets broadcast drug ads send viewers elsewhere for full risk information. HHS and FDA have said that change would make such ads "prohibitively long and expensive." The formal proposal is expected in December 2026.

When DeepIntent hired Colley in May 2026, Adweek tied the hire to restrictions under consideration that could affect more than $10 billion in annual pharma ad spending. That is the market Kopp Johnson's team sells into, and how the new rules apply to streaming and digital ads is still unclear.

The optimistic reading is that broadcast restrictions push money toward addressable, measurable channels, which is DeepIntent's business. The pessimistic reading is that regulators who start with TV ads rarely stop there.

The case for her is strong. She is one of the few revenue leaders in health ad tech who has worked at a top independent DSP, a top verification company and a vertical specialist, and that combination is exactly what DeepIntent's buyers move between. Holding company health agencies know her from IAS. National advertisers know her from The Trade Desk. Pharma media leads from Bayer, Amgen and Merck share panels with her. The AdExchanger honor was for team leadership, and the record supports it: she arrived at a company whose sale had just been blocked and helped steady it enough to attract a $637 million buyer within twenty months.

She also says things on stage that her lawyers might rather she didn't, such as "Five new states have recent regulatory changes or ones coming up." Most executives would leave that out of a sales pitch.

What her résumé cannot promise is control over the three things her quota now depends on. She does not decide whether DeepIntent's de-identification survives the next state's definition of health data. She does not decide whether the FDA's rule covers the inventory she sells. And she does not decide whether pharma procurement keeps accepting "up to 35%" from a beta study with no published sample size as proof of outcomes.

A seller with her experience knows the next stage of this market. Point-of-care ads, prescriber-level triggers and agentic planning will sell. Independent proof that they produce prescriptions is still missing.

She once said the "Year of" pressure was the jargon she couldn't stand. For DeepIntent, the year that matters is the one when someone other than DeepIntent measures the lift.

This profile was reported from public sources published between December 2019 and October 2026, including DeepIntent, The Trade Desk and IAS press releases and company pages, FTC and federal court filings in the IQVIA and Propel Media case, trade coverage in AdExchanger, Adweek, Fierce Pharma and PPC Land, lender and adviser announcements on the Vitruvian deal, and law firm analyses of federal and state health privacy rules. DeepIntent is privately held and does not disclose revenue, so the revenue figure cited is an outside shareholder's estimate and is labeled that way. Market share figures in the FTC complaint are redacted, and the outcome studies cited are DeepIntent's own and do not publish sample sizes or matching methods. ADOTAT has no financial relationship with DeepIntent or Lisa Kopp Johnson. DeepIntent did not review this piece before publication.